| Revenue Growth | Global revenue up 13% to $78M; Jeuveau global toxin up 11%. |
|---|---|
| Mgmt Confidence | High confidence in 2028 objectives and portfolio strategy execution. |
| Demand Visibility | Healthy aesthetics market; GLP-1 therapies driving new patient adoption. |
| Margin Trends | Adjusted gross margin 66.1%; full-year guidance 67% to 67.5%. |
| Op. Leverage | Revenue grew 14% year-to-date while non-GAAP expenses fell 2.5%. |
| Pricing Power | Portfolio growth rebates and bundling pilots driving deeper account penetration. |
| Vol vs Price | Growth driven by 500 new accounts and 23% rewards membership increase. |
| Segment Growth | HA business grew nearly 40% in Q3 and 50% year-to-date. |
| New Clients | Added over 500 purchasing accounts; cumulative base exceeds 19,000 customers. |
| Capex & Debt | Ended quarter with $41.7M cash; $120M additional non-GAAP capacity available. |
| Regulatory | FDA untitled letter for Instagram post; Sculpt approval expected Q4 2026. |
| Commentary | Shifted from single-product company to a diversified global performance beauty platform. |
| New Launches | Evolus Sculpt (2027), Lifts (2028), and Profilo (2030) planned launches. |
Growth
Global revenue grew 13% to $78M; HA business grew nearly 40% in Q3.
Outlook
Reaffirmed 2028 targets of $450M-$500M revenue and 13%-15% adjusted EBITDA margins.
Risks
Management received an FDA untitled letter regarding an Instagram post; seasonal Q3 softness noted.
The company's earnings call, NASDAQ: EOLS, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Evolus, Inc.: key numbers
- Share price
- $6.63Close, Nov 16
- Market cap
- $439M
- Shares outstanding
- 66.19MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Evolus, Inc.
All →Evolus Q3 2026 Results: Net Loss of $12.5M, Loss Narrows
Evolus, Inc. is an aesthetic neurotoxin company that has incurred significant losses since inception and relies heavily on its licensing agreements with Daewoong and Symatese. The company is currently focused on the commercial success of Jeuveau and the regulatory approval process for its Evolysse product line.
- Key figure
- Net loss $12.5M
Evolus Financial Results
Evolus reported Q3 2026 global net revenue of $78.0 million, a 13% increase year-over-year, driven by growth in its Jeuveau toxin and HA gel portfolio. The company achieved its fourth consecutive quarter of positive Adjusted EBITDA at $1.2 million and reaffirmed its full-year 2026 revenue guidance of $330 million to $337 million.
- Term
- Q3 2026
“Our third quarter results demonstrate the continued strength of our commercial execution and the progress we are making in building a diversified global performance beauty company. Jeuveau® remains a durable growth engine, and our hyaluronic acid (HA) gel portfolio is gaining meaningful share and becoming an increasingly important contributor to the business.”
David Moatazedi, President and Chief Executive Officer
“Along with our commercial progress, we are building a robust innovation pipeline that broadens our long-term opportunity. Our partnership with IBSA to develop and commercialize Profhilo® in the United States establishes the foundation for skin quality as a third category within our facial injectable platform.”
David Moatazedi, President and Chief Executive Officer